摘要
目的 探讨新型连续联合复方制剂安今益(雌二醇屈螺酮片)治疗女性绝经后症状的临床疗效、安全性和对血脂代谢影响.方法 采用配对对照回顾性临床研究,对2012年1月至2014年10月北京朝阳医院妇科门诊就诊接受安今益(1 mg 17β-雌二醇和2 mg屈螺酮/片,隔日1片)治疗绝经症状女性27例,和同时期同年龄段接受利维爱(tibolone 2.5 mg/片,隔日1片)治疗26例对照,收集临床资料,服药前、服药12周和停药2个月血清激素、血脂、空腹血糖水平,以及盆腔、乳腺和颈动脉血管超声数据.结果 两组对象年龄、绝经时间、体质量指数和临床患病情况具有可比性.服药前安今益组E2水平(12±10) ng/L,甘油三酯(TG) (2.0±1.1) mmol/L,脂蛋白a(LPa) (47±43) mmol/L;利维爱组E2水平(23 ±12) ng/L,TG(1.3±0.7)mmol/L,LPa(28±14) mmol/L.服药12周后安今益组E2水平(30 ±18) ng/L,TG (1.6±1.1) mmol/L,LPa(37±36) mmol/L;利维爱组E2水平(23 ±9) ng/L,TG(1.1±0.6) mmol/L,LPa(18±12) mmol/L.安今益组服药后子宫内膜厚度增加,23例服药中发生阴道出血.结论 安今益作为绝经后女性MHT连续联合治疗新型药物,能很好缓解绝经后相关症状,调节血脂代谢和保护心血管系统作用强于利维爱,阴道出血发生率高、子宫内膜增厚和乳腺胀痛不适降低了使用者依从性.
Objective To compare the clinical and metabolic effects of drospirenone-estradiol (Angeliq) versus tibolone (Livial) in postmenopausal women.Methods Twenty-seven postmenopausal women of group 1 took Angeliq (1 dose every two days) while another group 2 (n =26) received tibolone (2.5 mg every two days) as hormone replacement therapy for 12 weeks.A retrospective analysis was used to evaluate the clinical efficacy,safety and risk factors of cardiovascular metabolism.The clinical data were collected before and after treatment,including personal interview,medical examination and ultrasound imaging of pelvic,breast and carotid artery.Results No statistically significant inter-group differences existed in age or body mass index.Before treatment,the level of E2 was (12 ± 10) ng/L,triglyceride (TG) (2.0 ± 1.1) mmol/L,lipoprotein-a (LPa) (47 ± 43) mmol/L in group 1 versus (23 ± 12) ng/L,(1.3 ± 0.7) mmol/L and (28 ± 14) mmol/L in group 2.After 12-week treatment,(30 ± 18) ng/L,(1.6 ± 1.1) mmol/L and (37 ±36) mmol/L in group 1 versus (23 ±9) ng/L,(1.1 ±0.6) mmol/L and (18 ± 12) mmol/L in group 2.A greater incidence of vaginal bleeding and thicker endometrium were found in group 1.Conclusion Angeliq can relieve menopausal symptoms.And its functions of regulating lipid metabolism and protecting cardiovascular system are better than those of Livial.However,its wider acceptability is limited by vaginal bleeding,thicker endometrium and breast pain.
出处
《中华医学杂志》
CAS
CSCD
北大核心
2015年第23期1815-1818,共4页
National Medical Journal of China
关键词
绝经激素治疗
雌二醇屈螺酮
替勃龙
动脉粥样硬化性心血管疾病
Postmenopausal hormone replacement therapy
Estradiol-drospirenone combination
Tibolone
Carotid atherosclerotic disease